Development of erythrosine-based photodynamic therapy with a targeted drug delivery system to induce HepG2 cell apoptosis in vitro
Journal
BIOCHEMICAL ENGINEERING JOURNAL
Journal Volume
177
Date Issued
2022-01
Author(s)
Abstract
Photodynamic therapy (PDT) is an anticancer treatment that can trigger the ROS/JNK/caspase-3 apoptotic pathway, thus inducing cancer cell apoptosis by generating singlet oxygen and reactive oxygen species (ROS) from irradiating photosensitizers (PSs) at a specific optical wavelength. In this study, on the basis of the concept of third-generation PSs and drug repurposing, we fabricated a novel folic-acid-conjugated, chitosan-coated, erythrosine-embedded complex (FA–CS–ERY complex) for integrating PDT with a targeted drug delivery system. Folate receptors are highly expressed on cancer cells and rarely expressed on normal cells. The erythrosine delivered by the FA–CS–ERY complex could react with light at an excitation wavelength of 520–525 nm. The results indicated that the FA–CS–ERY complex was taken up by HepG2 cells and mainly located in cell nuclei. In addition, ROS generated by irradiating the FA–CS–ERY complex with green LED light induced apoptosis effectively. When the erythrosine concentration and irradiation fluence were 60 µM and 3.17 J/cm2, respectively, the relative HepG2 cell viability significantly decreased to only 3.2%. This cost-effective and low-irradiance PDT demonstrated higher performance than conventional anticancer therapies and thus may serve as an alternative option for cancer treatment.
Subjects
Folic acid; Erythrosine; Chitosan; HepG2; Photodynamic therapy (PDT); LIGHT-EMITTING DIODE; LIVER-CANCER; CHITOSAN; DYES; NANOPARTICLES; INACTIVATION; MODEL
SDGs
Other Subjects
Cell death; Chitosan; Controlled drug delivery; Cost effectiveness; Diseases; Organic acids; Oxygen; Photosensitizers; Targeted drug delivery; Cell apoptosis; Erythrosine; Folic acids; Hep-g2 cells; Hepg2; In-vitro; Photodynamic therapy; Photosensitiser;
Publisher
ELSEVIER
Type
journal article